Drug intelligence / Profile preview

LMY-232

Development stage: Preclinical
Lead developer: Luminary Therapeutics
Modality: CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
Administration: Intravenous

Overview

LMY-232 is a universal CAR-T cell therapy developed by Luminary Therapeutics. It is being investigated as a cell replacement and immunologic cytotoxicity agent, primarily targeting solid tumors and autoimmune diseases. The drug is currently in preclinical development, with its main therapeutic areas including neoplasms (solid tumors) and immune system diseases (autoimmune disorders). As a universal CAR-T therapy, it likely involves genetically engineered T cells designed to recognize and attack specific antigens on diseased cells[1][2][3].

Beyond the preview

Go deeper on LMY-232.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on LMY-232.

Explore the full profile